Anti-lipolytic agents like nicotinic acid derivatives may have therapeutic potential in acute myocardial ischaemia by reducing free fatty acid-induced metabolic crisis and arrhythmias, warranting future clinical trials.
Should not change acute ischaemia management; hypothesis-generating proposal warrants prospective trials.
Plasma free fatty acids (non-esterified fatty acids) increase in the first hour of the onset of acute myocardial ischaemia. This results from catecholamine stimulation of adipose tissue lipolysis. It can lead to a metabolic crisis in the injured myocardium with the development of ventricular arrhythmias and increased early mortality. Preconditioning, β-adrenergic blockade and glucose-insulin-potassium are possible therapeutic approaches, but anti-lipolytic agents, such as some nicotinic acid derivatives, can reduce plasma free fatty acid concentrations within minutes and have untried potential. A clinical trial of their effectiveness is needed from the first moment when a patient with an acute coronary syndrome is seen by paramedics.
No takes yet. Share an insight, caveat, or question.
Michael F. Oliver (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: